Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
Weekly News Roundup | 23 March 2026
Your essential life science news 23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...
Power Outages as a Clinical Risk Multiplier in Healthcare
Electricity as a Hidden Dependency in Healthcare Reliable electricity is a foundational requirement for modern healthcare systems. From acute hospital care to long-term residential facilities and home-based treatment, uninterrupted power underpins virtually every...
I’m a Menopause Doctor – Here’s the Real Problem with Fezolinetant
With news of a HRT alternative for women struggling with hot flushes now available on the NHS, Dr Louise Newson explains why when it comes to Fezolinetant, women need to proceed with caution. UK medicines regulator NICE reported that they're in the final stages of...
Statins Safer Than Previously Thought, Major Review Finds
Cholesterol-lowering drugs known as statins, taken by millions worldwide, are significantly safer than often perceived, according to a major new scientific analysis. Conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and published in The Lancet, the...
Lilly Finalizes “Lilly Lehigh Valley” with $3.5B Manufacturing Hub
Eli Lilly and Company has officially selected Fogelsville, Pennsylvania, as the site for its newest $3.5 billion injectable medicine and device manufacturing facility. Operating under the name "Lilly Lehigh Valley," the project represents the final piece of a quartet...
AstraZeneca Commits $15bn to Expand R&D and Manufacturing in China
AstraZeneca has announced plans to invest up to 15 billion US dollars to expand its research, development, and manufacturing operations in China, reinforcing the country’s role as a central pillar of the company’s global strategy. The long-term investment will fund...
Phacilitate Unites CGT Community for New Era Defined by Collaboration
Phacilitate announces the return of Advanced Therapies Week (ATW) for its 22nd year, reinforcing its status as one of the most established and influential cell and gene therapy (CGT) conferences in the United States and among the most recognized globally. In...
‘The World Has Not Yet Learned From the COVID Crisis’ Experts Warn
New research published (22 January 2026) in The Lancet Psychiatry warn that lessons have not been learned from the pandemic when it comes to mental health. The researchers recommend that mental health should be treated as a core consideration when it comes to pandemic...
Life Extending Prostate Cancer Drug to be Offered to Thousands in England
Thousands of men in England with advanced prostate cancer are set to gain access to a new life extending treatment following a decision by the National Institute for Health and Care Excellence. The move marks a significant development in the management of one of the...
EQT Targets Oxford Biomedica in Major Biotech Takeover Bid
Oxford Biomedica has officially confirmed it is in preliminary discussions with the Swedish private equity giant EQT regarding a potential cash takeover. The announcement follows significant market speculation and a sharp rise in the company’s share price on January...
Thermo Fisher Reshoring Surge: Strategic Shift to U.S. Manufacturing
In a move that signals a significant shift in the global pharmaceutical supply chain landscape, Thermo Fisher Scientific (NYSE: TMO) has announced a substantial influx of new contracts within its pharmaceutical services business. The common thread among these new...
UK Boosts Clinical Trials With Faster, Agile Regulation
Press Release: Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more...
The Research Partnership That Looked Perfect – Until it Wasn’t
The dream is always the same: strike out on your own and build something that’s truly yours. Perhaps you’re spinning out from a university, commercialising years of research with a fellow academic who shares your vision. Or maybe you’re breaking away from the big...
Science & Nuclear Leaders Urge Pause on Apprenticeship Reforms
Leaders in life sciences and nuclear urge review of proposed changes Leaders across the science sector have made an urgent call to government to reconsider potentially harmful reforms to the way apprenticeships are assessed. Members of two leading employer bodies...
The Lost World of Autism
Dhruv Shenai explores how females have been left behind in conversations on autism by discussing the history and lack of female representation within the field. Neuroscientist Gina Rippon has spent years challenging the male-centred bias in autism research. Her new...







